October 23, 2020
Business News

LB Pharmaceuticals Inc Secures $10.0 Million in Additional Financing


NEW YORK–()–LB Pharmaceuticals Inc, a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, today announced the closing of a $10.0 million convertible note offering through a private placement to existing and new investors. The notes are structured to convert into equity as part of the Company’s Series B financing. Proceeds from this convertible note financing will support continued clinical development of the Company’s lead asset, LB-102. A PET imaging study is planned for later this year and a First-in-Patient Phase 2 clinical trial evaluating the effectiveness of LB-102 in treating the symptoms of schizophrenia is planned for…



Click here to view the original article.

Related Posts

You might also like ...

Schlumberger gibt Finanzergebnisse des dritten Quartals 2020 bekannt
OFG Bancorp Reports 3Q20 Results
Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis